Literature DB >> 26776758

IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes.

Eugene Hughes1.   

Abstract

In type 2 diabetes (T2D), treatment is optimised to minimise hyperglycaemia and the risk of microvascular complications. While there are a number of effective treatments, intensive treatment is associated with negative side effects such as increased hypoglycaemia and weight gain. With complementary modes of action, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and a basal insulin in combination offer an alternative to basal-bolus therapy in T2D. This review describes the rationale behind this treatment combination and presents clinical data available for IDegLira, the first basal insulin (insulin degludec) and GLP-1RA (liraglutide) co-formulation available in one pen for a single injection daily.
Copyright © 2016 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  GLP-1; Insulin; Intensification; Type 2 diabetes

Mesh：

Substances：

Year:  2016        PMID： 26776758     DOI： 10.1016/j.pcd.2015.12.005

Source DB:  PubMed          Journal:  Prim Care Diabetes        ISSN： 1878-0210            Impact factor:   2.459


  6 in total

1.  Transitioning to Fixed-Ratio Combination Therapy: Five Frequently Asked Questions Health Care Providers Should Anticipate From Their Patients.

Authors:  Ian Blumer; Lucia M Novak; Steven Edelman; Tricia Santos Cavaiola
Journal:  Clin Diabetes       Date:  2019-10

2.  Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study.

Authors:  Hermione Price; Matthias Blüher; Rudolf Prager; Tra-Mi Phan; Brian L Thorsted; Bernd Schultes
Journal:  Diabetes Obes Metab       Date:  2018-01-11       Impact factor: 6.577

3.  Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin.

Authors:  L Meneghini; A Doshi; D Gouet; T Vilsbøll; K Begtrup; P Őrsy; M F Ranthe; I Lingvay
Journal:  Diabet Med       Date:  2019-11-28       Impact factor: 4.359

4.  How Effective Is the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) in Different Patient Populations, and When Should It Be Used in Clinical Practice?

Authors:  Joseph Tibaldi; Max E Mercado; Jodi Strong
Journal:  Clin Diabetes       Date:  2020-10

Review 5.  Forum for Injection Technique and Therapy Expert Recommendations, India: The Indian Recommendations for Best Practice in Insulin Injection Technique, 2017.

Authors:  Nikhil Tandon; Sanjay Kalra; Yatan Pal Singh Balhara; Manash P Baruah; Manoj Chadha; Hemraj B Chandalia; K M Prasanna Kumar; S V Madhu; Ambrish Mithal; Rakesh Sahay; Rishi Shukla; Annamalai Sundaram; Ambika G Unnikrishnan; Banshi Saboo; Vandita Gupta; Subhankar Chowdhury; Jothydev Kesavadev; Subhash K Wangnoo
Journal:  Indian J Endocrinol Metab       Date:  2017 Jul-Aug

6.  Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec-Liraglutide (Ideglira).

Authors:  Luciano Zenari; Andrea Da Porto; Lorena De Moliner; Francesca Lugli; Valeria Guazzoni; Gloria Groppelli; Laura Molteni; Massimo Bracaccia; Vera Frison; Natalino Simioni; Barbara Bonsembiante; Cesare Miranda; Annunziata Lapolla
Journal:  Diabetes Ther       Date:  2020-10-26       Impact factor: 2.945
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.